AstraZeneca’s lung cancer drug obtains China’s approval

AstraZeneca’s lung cancer drug obtains China’s approval

Pharmaceuticals giant AstraZeneca Plc’s lung cancer pill Tagrisso has finally obtained Chinese authorities’ approval.

Tagrisso has been developed to help cancer patients with certain deadly genetic mutations that are quite common in China, the world’s most populous country. It is the first cancer drug approved by the China Food & Drug Administration’s precedence review pathway.

Sean Bohen, executive VP of AstraZeneca, said, “This is an important step forward for Tagrisso and a significant opportunity to bring a breakthrough medicine to patients with NSCLC in China, where EGFR mutation rates are some of the highest in the world.”

The regulatory approval has boosted the British pharmaceutical firm’s prospects in a crucial therapy area. Lung cancer has been a key component of AstraZeneca’s ambitious cancer drug sales targets set in 2014 in response to an acquisition attempt by Pfizer.

At the time, some analysts viewed the drug’s sales target as unrealistic. However, consensus forecast fort he drug has now jumped to $2.8 billion for 2022. Last year, Tagrisso generated $423 million for the company.


Whether you want to ask us a question, would like to solve a problem, or just give us a suggestion, you’ll find many ways to contact us right here.


Phone: (916) 225-9835

Fax: (916) 225-9845


Subscribe and get the latest updates, news and more...